植物次生代谢产物及其衍生物的抗肿瘤成药研究进展  

Advances in discovering anticancer agents from plant secondary metabolites and their derivatives

作　　者：王红晓[1] 闵军霞[1,2] 

机构地区：[1]浙江大学医学院第一附属医院,杭州310003 [2]浙江大学转化医学研究院,杭州310058

出　　处：《生命科学》2015年第8期1005-1019,共15页Chinese Bulletin of Life Sciences

基　　金：浙江省自然科学基金重点项目(LZ15H160002)

摘　　要：面对严重威胁健康的肿瘤,人类从未间断过抗肿瘤药物的研发。纵观历史,从非选择性的化疗药物,到特异性阻断驱动致癌基因的靶向药物,直到今天以患者为中心的个体化肿瘤治疗,抗癌药物迅猛发展,成为提高肿瘤患者生存率的重要治疗手段。然而,由于大多数抗癌药物存在难以克服的短期耐药及毒副作用等问题,严重影响临床治疗效果。近年,筛选植物来源的天然提取物及其次生代谢产物的抗癌作用,倍受关注并取得令人瞩目的进展,包括临床广泛应用的紫杉醇、长春新碱、依托泊苷及喜树碱等。总结植物的抗肿瘤活性成分、筛选方法、潜在作用机制及临床应用等国内外研究现状,旨在为植物来源的抗肿瘤药物的深入研发提供参考。Cancer is a big threat to human beings. From historical perspective, it goes through two paradigm shifts in anticancer drug discovery. The first is from ＂non-selective chemotherapeutics＂ to highly selective ＂molecular targeted cancer therapeutics＂, and the second is from ＂disease centered＂ drug discovery phase to the ＂patient-centered＂ personalized cancer therapeutics. Although much progress has been made, there are still limited effective options for most cancer patients. Recently, a great attention has been paid to screening effective components from plant extracts, including the most widely used chemotherapy agents such as paclitaxel, vincristine, etoposide, and irinotecan. In this review article, we summarize the current progress of the antitumor activity of plant extracts, the proposed potential molecular mechanisms, clinical application, and screening methods. In addition, this review explores and discusses potential strategies to facilitate discovery of effective anticancer agents from plant secondary metabolites and the derivatives.

关 键 词：植物抗癌药 肿瘤治疗 药物筛选 次生代谢物 

分 类 号：S567[农业科学—中草药栽培] R979.19[农业科学—作物学]